Department of Ophthalmology, University Hospital, LMU Munich, Munich, Germany.
Ocul Immunol Inflamm. 2024 Sep;32(7):1395-1399. doi: 10.1080/09273948.2023.2250431. Epub 2023 Sep 1.
To evaluate the long-term outcomes of patients with non-infectious uveitis treated with 0.19 mg fluocinolone acetonide insert (FAi) for up to 36 months in clinical practice.
A retrospective study conducted at a single uveitis center.
Fifty eyes of 39 patients were included. Mean best corrected visual acuity (BCVA) and central retinal thickness (CRT) remained stable until month 36 after FAi implantation (61.04 vs. 70.25 letters and 370.8 vs. 332.5 µm, respectively). The recurrence rate was 34% (17 eyes) after 36 months, of which 82% (14 eyes) received high-dose corticosteroids before FAi. Mean intraocular pressure (IOP) remained unchanged (13.38 vs. 15.74 mmHg), while most phakic eyes (13 of 14 eyes) required cataract surgery.
We show that FAi effectively prevents recurrences of non-infectious uveitis for up to three years in clinical practice, comparable with randomized clinical trials. Patients who received high-dose corticosteroids before FAi have an increased risk for early recurrence and should be considered for scheduled re-treatment.
评估在临床实践中使用 0.19mg 氟轻松醋酸酯植入物（FAi）治疗长达 36 个月的非感染性葡萄膜炎患者的长期结局。
这是在单一眼葡萄膜炎中心进行的回顾性研究。
共纳入 39 名患者的 50 只眼。FAi 植入后 36 个月时，最佳矫正视力（BCVA）和中心视网膜厚度（CRT）均值保持稳定（分别为 61.04 个字母和 70.25 个字母，370.8µm 和 332.5µm）。36 个月后复发率为 34%（17 只眼），其中 82%（14 只眼）在使用 FAi 前接受了高剂量皮质类固醇治疗。眼内压（IOP）均值保持不变（13.38mmHg 和 15.74mmHg），而大多数有晶状体眼（14 只眼中的 13 只）需要接受白内障手术。
我们表明，FAi 在临床实践中可有效预防非感染性葡萄膜炎长达三年的复发，与随机临床试验相当。在使用 FAi 前接受高剂量皮质类固醇治疗的患者复发风险增加，应考虑进行计划的再治疗。
